Natco Pharma Q4FY26 Results: Revenue ₹8,169 Cr, PAT ₹2,690 Cr
Natco Pharma reported Q4FY26 revenue of ₹8,169 crore and PAT of ₹2,690 crore. FY26 revenue reached ₹43,759 crore with PAT of ₹14,185 crore. The company launched Semaglutide and Pomalidomide, and acquired a stake in Adcock Ingram. An earnings call is scheduled for May 29, 2026.
The announcement includes detailed financial results for both the quarter and the full fiscal year, along with key business developments, product launches, and strategic investments, which are material information for investors.
The company reported strong financial results for the quarter and the full year, including significant revenue and profit figures. Product launches and strategic acquisitions also contribute to a positive outlook.
Natco Pharma Limited announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a total revenue of ₹8,169 crore for Q4FY26, with Pharma Export Formulations contributing ₹5,396 crore and Domestic Formulations at ₹1,087 crore. Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA) stood at ₹2,054 crore, with an EBITDA margin of 25.1%.
Profit after tax (PAT) for Q4FY26 was ₹2,690 crore, reflecting a profit margin of 36.4%. This includes a one-time benefit of ₹1,150 crore due to the company's election to move to the new tax regime, which led to a remeasurement of its deferred tax asset on MAT credit. The earnings per share (EPS) for the quarter was ₹14.96.
For the full fiscal year FY26, Natco Pharma reported a total revenue of ₹43,759 crore. EBITDA for the year was ₹17,341 crore, with an EBITDA margin of 39.6%. The PAT for FY26 was ₹14,185 crore, resulting in a profit margin of 32.4% and an EPS of ₹79.20.
Key business highlights for Q4FY26 include the launch of Semaglutide Multi Dose Vials in India at an affordable price and the launch of Pomalidomide Capsules in the U.S. market. For FY26, the company launched Risdiplam for Spinal Muscular Atrophy in India and Everolimus tablets and Bosentan tablets in the U.S. market. The company also completed a strategic acquisition of a 35.75% stake in Adcock Ingram Holdings Limited, South Africa.
Natco Pharma also provided an update on its product pipeline, including key Para IV products and NCE investments. The company is investing in biotechnology companies like eGenesis and Cellogen Therapeutics, focusing on xenotransplantation and CAR-T cell therapies respectively.
An earnings call is scheduled for May 29, 2026, at 4:30 PM IST to discuss the company's operational and financial performance.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.